stoxline Quote Chart Rank Option Currency Glossary
Enzo Biochem, Inc. (ENZ)
1.38  0.03 (2.22%)    02-23 16:00
Open: 1.35
High: 1.38
Volume: 100,821
Pre. Close: 1.35
Low: 1.34
Market Cap: 70(M)
Technical analysis
2024-02-23 4:36:23 PM
Short term     
Mid term     
Targets 6-month :  1.64 1-year :  1.92
Resists First :  1.4 Second :  1.64
Pivot price 1.32
Supports First :  1.28 Second :  1.2
MAs MA(5) :  1.35 MA(20) :  1.31
MA(100) :  1.33 MA(250) :  1.64
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  76.6 D(3) :  71.6
RSI RSI(14): 57.9
52-week High :  2.74 Low :  1
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ENZ ] has closed below upper band by 22.0%. Bollinger Bands are 20.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.38 - 1.39 1.39 - 1.39
Low: 1.33 - 1.33 1.33 - 1.34
Close: 1.37 - 1.38 1.38 - 1.39
Company Description

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Headline News

Tue, 20 Feb 2024
Is Enzo Biochem Inc (ENZ) Stock a Bad Value? - InvestorsObserver

Tue, 13 Feb 2024
Jim Simons Trims Stake in Enzo Biochem Inc - Yahoo Finance

Fri, 09 Feb 2024
Should You Hold Enzo Biochem Inc (ENZ) Stock Friday Morning? - InvestorsObserver

Thu, 01 Feb 2024
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments - GlobeNewswire

Mon, 29 Jan 2024
Here's Why Laughing Water Capital Sold Enzo Biochem Inc (ENZ) - Yahoo Finance

Mon, 18 Dec 2023
HEICO, EMCOR Group And 3 Stocks To Watch Heading Into Monday - Enzo Biochem (NYSE:ENZ), EMCOR Group (NYSE - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Diagnostics & Research
Shares Out 50 (M)
Shares Float 39 (M)
Held by Insiders 24.2 (%)
Held by Institutions 40.1 (%)
Shares Short 755 (K)
Shares Short P.Month 994 (K)
Stock Financials
EPS -0.51
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.47
Profit Margin 76.5 %
Operating Margin -70.2 %
Return on Assets (ttm) -16.8 %
Return on Equity (ttm) -42.5 %
Qtrly Rev. Growth 9.8 %
Gross Profit (p.s.) 0
Sales Per Share 0.62
EBITDA (p.s.) -0.47
Qtrly Earnings Growth 0 %
Operating Cash Flow -42 (M)
Levered Free Cash Flow 5 (M)
Stock Valuations
PE Ratio -2.71
PEG Ratio 0
Price to Book value 0.93
Price to Sales 2.19
Price to Cash Flow -1.68
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android